GLP-1
-
Understanding the ‘GLP-1 Divorce’ Phenomenon in Modern Relationships
The ‘GLP-1 divorce’ trend highlights how weight loss medications can act as catalysts, revealing pre-existing relationship tensions during lifestyle shifts.
-
Todd Engel Files Lawsuit After Ozempic Use Precedes Vision Loss
Maryland resident Todd Engel has filed a lawsuit against Novo Nordisk after suffering permanent vision loss in both eyes following Ozempic use.
-
GLP-1 Drugs Linked to Lower Fracture Risk in Type 2 Diabetes Patients
A study of 133,000 patients shows GLP-1 medications may lower fracture risk in those with type 2 diabetes, challenging previous concerns about bone health.
-
The Ozempic Effect: How Weight-Loss Drugs Are Upending Workplace Etiquette
The rise of GLP-1 weight-loss drugs is sparking uncomfortable body-focused conversations and HR dilemmas, blurring traditional professional boundaries.
-
For GLP-1 Users, the In-Store Clothes Shopping Trip Is Back
As GLP-1 weight-loss drug users navigate changing sizes, they are increasingly returning to brick-and-mortar stores to rebuild their wardrobes.
-
New Study Links GLP-1 Weight Loss Drugs to Increased Alopecia Risk
A study in The BMJ suggests GLP-1 agonists like Ozempic may increase non-scarring alopecia risk, likely due to rapid weight loss rather than the drugs themselves.
-
Rosie O’Donnell Credits GLP-1 Drug Mounjaro for ‘Saving’ Her Life Ahead of Late-Night Hosting Return
Rosie O’Donnell credited the GLP-1 drug Mounjaro with saving her life and opened up about her weight loss journey ahead of guest-hosting Jimmy Kimmel Live!
-
FDA Approves Eli Lilly’s Once-Daily Weight-Loss Pill Foundayo
The FDA has approved Eli Lilly’s orforglipron, branded as Foundayo, offering a flexible, once-daily oral option for weight management starting this April.
-
Medical Weight Loss Collides With Body Positivity Standards
The rise of GLP-1 medications is reshaping fashion and public discourse, sparking a debate on bodily autonomy, medical ethics, and the future of inclusion.
-
Eli Lilly Surges After FDA Approves Foundayo Obesity Pill
Eli Lilly shares rose 4% following FDA approval of Foundayo, an oral GLP-1 medication for weight loss, signaling a major shift in the obesity treatment market.
-
GLP-1 Drugs Linked to Lower Colon Cancer Risk in New Study
New research presented at the 2026 ASCO Gastrointestinal Cancers Symposium suggests GLP-1 receptor agonists may reduce colorectal cancer incidence by 36% compared to aspirin.
-
Beyond Obesity: The Emerging Risks of GLP-1 Medications
As GLP-1 drugs gain popularity for weight loss, new studies highlight potential long-term risks for bone health and metabolism, sparking a debate on their role in modern medicine.
-
Novo Nordisk Boosts Oral GLP-1 Production Amid Intensifying Competition
Novo Nordisk commits €432 million to scale oral GLP-1 production in Ireland, solidifying its chronic disease treatment focus.
-
McDonald’s Reports Strong Q4 Amid 2026 Menu Shifts and Value Push
McDonald’s exceeded Q4 2025 sales and earnings expectations, driven by value promotions and marketing. The company is now adapting its 2026 menu for GLP-1 drug users, expanding McCafé offerings, and bringing back the popular Shamrock Shake.
-
Serena Williams Stars in Ro’s Super Bowl Ad, Highlighting GLP-1 Health Benefits
Ro’s first Super Bowl commercial, featuring Serena Williams, aims to shift the narrative around GLP-1 medications by showcasing their significant health benefits beyond weight loss, based on Williams’s personal experience.